期刊
LEUKEMIA & LYMPHOMA
卷 55, 期 2, 页码 371-377出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2013.805759
关键词
AML; LEF1; intermediate-risk cytogenetics; fusion genes
资金
- National Natural Science Foundation of China [81170486, 81170485, 81101498]
- Scientific Research Foundation from the Ministry of Education of China [43-NJYKDX-3]
- Jiangsu Province's Medical Elite Program [RC2011168]
- Key Project of Jiangsu Province Health Agency [K201107]
- Liu Da Ren Cai Gao Feng Project [2012-WS- 017]
- Priority Academic Program Development of Jiangsu Higher Education Institute [JX10231801]
Lymphoid enhancer-binding factor 1 (LEF1) is a downstream effector of the Wnt/beta-catenin signaling pathway and its dysregulation is associated with a number of malignant diseases such as leukemia. We explored the expression profile of LEF1 in acute myeloid leukemia (AML) and determined its specific prognostic significance in this disease. The LEF1 mRNA level in patients with previously untreated AML was significantly higher than in normal controls. Patients with AML with relatively higher LEF1 expression were more likely to achieve a complete remission (CR) following induction therapy in comparison to those with a lower LEF1 level. Moreover, we provide the first evidence that primary AML samples with AML1-ETO or PML-RAR alpha have a higher LEF1 level compared with those without each fusion gene. High LEF1 expression predicts a significantly better overall survival for patients with intermediate-risk cytogenetics. High LEF1 level was associated with a favorable relapse-free survival in patients with FLT3-ITD wild-type. Finally, a scoring system based on LEF1 level and mutation status of FLT3-ITD or NPM1 is reliable to predict the outcome for AML with intermediate-risk cytogenetics. Our results indicate that LEF1 contributes to the pathophysiology of AML and could serve as a novel predictor of better treatment response. LEF1 level may be incorporated into an improved risk classification system for certain specific subtypes of AML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据